Related Experiment Videos
Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder
1Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA.
Abstract:
Transforming growth factor (TGF) beta, a potent growth inhibitor of proliferation in most cells, usually exerts its effects through an interaction with membrane receptors, type I (TbetaR-I) and type II (TbetaR-II). In the present study, the expression of TGF-beta receptors was correlated with tumor grade, pathological stage, and probability of progression and survival in patients with bladder transitional cell carcinoma (TCC). To this end, immunohistochemistry was carried out in specimens obtained from 59 patients who underwent either radical cystectomy or transurethral resection of bladder tumor. Among these patients, 18 (30.5 %) had loss of TbetaR-I expression, whereas 27 (44.0%) had loss of TbetaR-II expression. There was a correlation between the loss of expression of TbetaR-I and TbetaR-II and the tumor grade (P = 0.041 and P = 0.026, respectively). In addition, both pathological and lymph node status also were associated with the loss of TbetaR-I and TbetaR-II expression (P = 0.025 and P = 0.004, respectively). Interestingly though, only the loss of expression of TbetaR-I was associated with an increased probability of tumor progression and a decreased probability of survival (P = 0.0046 and P = 0.0022, respectively). These results suggest that the status of TbetaR-I expression may be a potential prognostic marker in patients with bladder TCC.
Insights
Loss of transforming growth factor-beta receptor type I (TbetaR-I) expression in bladder cancer correlates with higher tumor grade and poorer survival. This suggests TbetaR-I may serve as a prognostic marker for bladder transitional cell carcinoma.
Area of Science:
- Oncology
- Cell Biology
- Molecular Pathology
Background:
- Transforming growth factor-beta (TGF-β) is a key regulator of cell proliferation, typically inhibiting it.
- TGF-β exerts its effects via membrane receptors: type I (TbetaR-I) and type II (TbetaR-II).
- Dysregulation of TGF-β signaling is implicated in various cancers, including bladder transitional cell carcinoma (TCC).
Purpose of the Study:
- To investigate the correlation between the expression of TGF-β receptors (TbetaR-I and TbetaR-II) and clinicopathological features of bladder TCC.
- To determine if TGF-β receptor expression status can predict tumor progression and patient survival in bladder TCC.
Main Methods:
- Immunohistochemistry was performed on 59 bladder TCC patient specimens.
- Expression levels of TbetaR-I and TbetaR-II were assessed.
- Correlations with tumor grade, pathological stage, lymph node status, tumor progression, and survival were analyzed.
Main Results:
- Loss of TbetaR-I expression was observed in 30.5% of patients; loss of TbetaR-II in 44.0%.
- Loss of both TbetaR-I and TbetaR-II expression correlated significantly with higher tumor grade and advanced pathological/lymph node status.
- Loss of TbetaR-I expression was specifically associated with increased tumor progression and decreased patient survival.
Conclusions:
- The expression status of TbetaR-I is significantly associated with tumor grade, pathological stage, and lymph node status in bladder TCC.
- Loss of TbetaR-I expression serves as a potential prognostic biomarker for predicting tumor progression and survival in patients with bladder TCC.